Drug Trial Radar · NCT01133951
Helicobacter Pylori Eradication to Prevent Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Oct 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3,000
Actual
Start
Jun 2010
Primary completion
Jan 2012
Study completion May 2032
Sponsor
- Lead sponsor
- Jie-Jun WangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 31, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 30 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients are killed by the terrible disease annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection appears to reduce the risk of gastric cancer. However, several recent controlled interventional trials by H. pylori eradication to prevent gastric cancer have yielded disappointing results. The exact effect of H.pylori eradication on prevention of gastric cancer is unclear up to now. To clarify this problem, the investigators conducted a prospective, randomized, double-blind, placebo-controlled, population-based study to determine whether H pylori eradication would reduce the incidence of gastric cancer in a high-risk population in China.
Conditions
- Helicobacter Infections
- Stomach Neoplasms
Interventions
OAC triple therapyDrug
Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
PlaceboDrug
Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Gastric cancer incidenceTime frame: 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhao-Lai Hua M.D.
Yangzhong, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.